• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance.

作者信息

Yap Christina, Rekowski Jan, Ursino Moreno, Solovyeva Olga, Patel Dhrusti, Dimairo Munyaradzi, Weir Christopher J, Chan An-Wen, Jaki Thomas, Mander Adrian, Evans Thomas R Jeffry, Peck Richard, Hayward Kathryn S, Calvert Melanie, Rantell Khadija Rerhou, Lee Shing, Kightley Andrew, Hopewell Sally, Ashby Deborah, Garrett-Mayer Elizabeth, Isaacs John, Golub Robert, Kholmanskikh Olga, Richards Dawn P, Boix Oliver, Matcham James, Seymour Lesley, Ivy S Percy, Marshall Lynley V, Hommais Antoine, Liu Rong, Tanaka Yoshiya, Berlin Jordan, Espinasse Aude, de Bono Johann

机构信息

Institute of Cancer Research, London SM2 5NG, UK

Institute of Cancer Research, London SM2 5NG, UK.

出版信息

BMJ. 2023 Oct 20;383:e076386. doi: 10.1136/bmj-2023-076386.

DOI:10.1136/bmj-2023-076386
PMID:37863491
Abstract
摘要

相似文献

1
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance.提高早期剂量探索性临床试验方案的质量和影响力：《标准方案条目：建议与阐释（SPIRIT）剂量探索扩展版（SPIRIT-DEFINE）指南》
BMJ. 2023 Oct 20;383:e076386. doi: 10.1136/bmj-2023-076386.
2
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols.SPIRIT-DEFINE解释与阐述：提高早期剂量探索性临床试验方案质量与影响力的建议
EClinicalMedicine. 2025 Jan 10;79:102988. doi: 10.1016/j.eclinm.2024.102988. eCollection 2025 Jan.
3
Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study.共识驱动的 SPIRIT 和 CONSORT 扩展在早期阶段剂量发现试验中的发展：DEFINE 研究。
BMC Med. 2023 Jul 5;21(1):246. doi: 10.1186/s12916-023-02937-0.
4
SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol.早期阶段剂量发现临床试验的 SPIRIT 和 CONSORT 扩展：DEFINE（剂量发现扩展）研究方案。
BMJ Open. 2023 Mar 29;13(3):e068173. doi: 10.1136/bmjopen-2022-068173.
5
Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension.试验方案中报告结果的指南：SPIRIT-结果2022扩展版
JAMA. 2022 Dec 20;328(23):2345-2356. doi: 10.1001/jama.2022.21243.
6
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance.提高早期剂量发现临床试验的报告质量和影响力：CONSORT 剂量发现扩展（CONSORT-DEFINE）指南。
BMJ. 2023 Oct 20;383:e076387. doi: 10.1136/bmj-2023-076387.
7
Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement.《析因随机临床试验方案的共识声明：SPIRIT 2013 声明的扩展》。
JAMA Netw Open. 2023 Dec 1;6(12):e2346121. doi: 10.1001/jamanetworkopen.2023.46121.
8
Assessment of clinical trial protocols for pathology content using the SPIRIT-Path guidelines highlights areas for improvement.使用 SPIRIT-Path 指南评估包含病理学内容的临床试验方案，突出了需要改进的领域。
J Pathol Clin Res. 2022 Sep;8(5):411-421. doi: 10.1002/cjp2.274. Epub 2022 May 31.
9
SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials.SPIRIT-PRO 扩展说明和阐述：临床试验方案中纳入患者报告结局的指南。
BMJ Open. 2021 Jun 30;11(6):e045105. doi: 10.1136/bmjopen-2020-045105.
10
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension.患者报告结局纳入临床试验方案指南：SPIRIT-PRO 扩展
JAMA. 2018 Feb 6;319(5):483-494. doi: 10.1001/jama.2017.21903.

引用本文的文献

1
SPIRIT 2025 statement: updated guideline for protocols of randomized trials.《SPIRIT 2025声明：随机试验方案的更新指南》
Nat Med. 2025 Apr 29. doi: 10.1038/s41591-025-03668-w.
2
SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials.《SPIRIT 2025解释与阐述：随机试验方案更新指南》
BMJ. 2025 Apr 28;389:e081660. doi: 10.1136/bmj-2024-081660.
3
SPIRIT 2025 statement: updated guideline for protocols of randomised trials.《SPIRIT 2025声明：随机试验方案的更新指南》
BMJ. 2025 Apr 28;389:e081477. doi: 10.1136/bmj-2024-081477.
4
SPIRIT 2025 statement: Updated guideline for protocols of randomised trials.《SPIRIT 2025声明：随机试验方案的更新指南》
PLoS Med. 2025 Apr 28;22(4):e1004589. doi: 10.1371/journal.pmed.1004589. eCollection 2025 Apr.
5
Barriers to publishing early phase clinical trials: the oncologists' perspective.早期临床试验发表的障碍：肿瘤学家的观点。
Oncologist. 2025 Apr 4;30(4). doi: 10.1093/oncolo/oyaf042.
6
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols.SPIRIT-DEFINE解释与阐述：提高早期剂量探索性临床试验方案质量与影响力的建议
EClinicalMedicine. 2025 Jan 10;79:102988. doi: 10.1016/j.eclinm.2024.102988. eCollection 2025 Jan.
7
Macrophage Therapy for Acute Liver Injury (MAIL): a study protocol for a phase 1 randomised, open-label, dose-escalation study to evaluate safety, tolerability and activity of allogeneic alternatively activated macrophages in patients with paracetamol-induced acute liver injury in the UK.巨噬细胞治疗急性肝损伤（MAIL）：一项1期随机、开放标签、剂量递增研究的方案，旨在评估英国对乙酰氨基酚诱导的急性肝损伤患者中同种异体交替活化巨噬细胞的安全性、耐受性和活性。
BMJ Open. 2024 Dec 9;14(12):e089417. doi: 10.1136/bmjopen-2024-089417.
8
Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtable.推进以患者为中心的护理：在早期临床试验中整合患者报告的结果用于耐受性评估——来自专家虚拟圆桌会议的见解
EClinicalMedicine. 2024 Sep 24;76:102838. doi: 10.1016/j.eclinm.2024.102838. eCollection 2024 Oct.
9
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance.提高早期剂量发现临床试验的报告质量和影响力：CONSORT 剂量发现扩展（CONSORT-DEFINE）指南。
BMJ. 2023 Oct 20;383:e076387. doi: 10.1136/bmj-2023-076387.